Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases
Major Depressive Disorder
About this trial
This is an interventional treatment trial for Major Depressive Disorder focused on measuring Depression, Neurofeedback, Amygdala
Eligibility Criteria
Inclusion Criteria:
- clinical diagnosis of major depressive disorder
- right handed
- adult aged 18-55
- currently depressed
Exclusion Criteria:
- clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder
- met Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for alcohol and/or substance abuse or substance dependence (other than nicotine) within 12 months prior to screening
- endorse suicidal intent or have made a suicide attempt within the preceding three months
- history of traumatic brain injury
- inability to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body)
- current pregnancy or breast feeding
- a primary language other than English
- received psychotropic drugs for at least 3 weeks (8 weeks for fluoxetine) prior to scanning (Effective medications will not be discontinued for the purposes of the study)
Sites / Locations
- Laureate Institute for Brain Research
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
real-time fMRI neurofeedback: Amygdala
real-time fMRI neurofeedback: HIPS
Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.